Acetoxy Empagliflozin
| CAS No. | 915095-99-7 | Cat. No. | BCP17275 |
| Name | Acetoxy Empagliflozin | ||
| Synonyms | BI10773; BI-10773; BI 10773; CE0108; CS0940; PB23119; VA10802; AJ93046; | ||
| Formula | C30H33ClO11 | M. Wt | 605.03 |
| Description | Empagliflozin, also known as BI10773 (trade name Jardiance), is drug approved for the treatment of type 2 diabetes in adults in 2014. It was developed by Boehringer Ingelheim and Eli Lilly and Company. Empagliflozin is an inhibitor of the sodium glucose co-transporter-2 (SGLT-2), and causes sugar in the blood to be absorbed by the kidneys and eliminated in urine. Empagliflozin is an inhibitor of the sodium glucose co-transporter-2 (SGLT-2), which is found almost exclusively in the proximal tubules of nephronic components in the kidneys. SGLT-2 accounts for about 90 percent of glucose reabsorption into the blood. | ||
| Pathways | Ion Channel/Membrane Transporter GPCR/G Protein | ||
| Targets | SGLT | ||
Structure
Part data of this page collected from the open network resources, so Biochempartner can not guarantee its accuracy.
For product details of different batches, please contact our Customer
- Service & Tech Support:orders@biochempartner.com
- Website:www.biochempartner.com
Products are for research use only and not for human use. We do not sell to patients.